Logo

UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

Share this
UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

Shots:

  • The ongoing BE BRIGHT- OLE trial evaluates the safety- tolerability- and efficacy of bimekizumab (q4w/q8w) in 989 patients with the mod. to sev. PsO
  • The interim data showed that @16wks.- 9/10 patients achieved clear or almost clear skin (IGA 0/1)- 8/10 patients achieved complete skin clearance (PASI 100) and maintained responses through 2yrs. with continuous maintenance dosing
  • Bimekizumab is an investigational humanized IgG1 mAb that selectively inhibits both IL-17A & IL-17F. The therapy is currently under the FDA’s review for the mod. to sev. PsO in adults while EC’s decision on MAA is expected within ~ 2mos of CHMP’s opinion

| Ref: PR Newswire | Image: Contract Pharma

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions